Article info
Editors’ commentary
Highlights from this issue
Citation
Highlights from this issue
Publication history
- First published November 23, 2020.
Online issue publication
November 23, 2020
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Clinical outcomes and risk factors for posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a multicentric case–control study
- Presymptomatic and longitudinal neuroimaging in neurodegeneration—from snapshots to motion picture: a systematic review
- Oxaliplatin-induced posterior reversible encephalopathy syndrome (PRES)
- Neurofilament light chain as a biomarker in neurological disorders
- Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications
- Systematic, comprehensive, evidence-based approach to identify neuroprotective interventions for motor neuron disease: using systematic reviews to inform expert consensus
- Identifying key signs of motor neurone disease in primary care: a nested case–control study using the QResearch database
- Ophthalmic manifestations of myelin oligodendrocyte glycoprotein-IgG-associated disorder other than optic neuritis: a systematic review
- Posterior reversible encephalopathy syndrome (PRES): diagnosis and management
- Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansions of C9ORF72